Form 4: Director Roush Acquires LMAT Shares via Vesting

Lemaitre Vascular Director John A. Roush acquired five shares of common stock through the release of dividend equivalent rights tied to restricted and performance stock units.

Summary

• John A. Roush, a Director at Lemaitre Vascular Inc. (LMAT), acquired a total of 5 shares of common stock.
• These shares were acquired on December 8, 2025, at a price of $0 per share.
• The acquisition resulted from the release of dividend equivalent rights.
• 2 shares were from dividend equivalent rights connected to a restricted stock unit (RSU) award granted on December 8, 2023.
• 3 shares were from dividend equivalent rights connected to a performance stock unit (PSU) award granted on December 8, 2023.
• Following these transactions, Roush directly beneficially owns 2,919 shares and 2,922 shares, and indirectly owns 181 shares through his spouse.
• He also beneficially owns 4.2075 dividend equivalent rights (related to RSU) and 3.8393 dividend equivalent rights (related to PSU).

Sentiment

Score: 6

Explanation: Slightly positive as an insider increased their stake, albeit a small amount from routine equity vesting. No significant financial impact or strategic shift indicated.

Positives

• Director John A. Roush increased his direct beneficial ownership of Lemaitre Vascular Inc. common stock by 5 shares.
• The acquisition of shares through dividend equivalent rights indicates the vesting of previously granted equity awards (RSUs and PSUs), suggesting continued alignment of management interests with shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor positive signal of insider ownership increase, aligning interests with company performance.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of a small number of shares by a director through the vesting of equity awards. While it indicates continued insider ownership and alignment, the transaction size is not significant enough to warrant a change in investment recommendation. The filing provides no new information regarding the company's operational performance, financial health, or strategic direction that would alter a fundamental investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Lemaitre Vascular, LMAT, SEC Form 4, Insider Transaction, Stock Acquisition, Director, Equity Vesting, Dividend Equivalent Rights, Restricted Stock Unit, Performance Stock Unit